265 related articles for article (PubMed ID: 26137407)
1. GITR agonist enhances vaccination responses in lung cancer.
Zhu LX; Davoodi M; Srivastava MK; Kachroo P; Lee JM; St John M; Harris-White M; Huang M; Strieter RM; Dubinett S; Sharma S
Oncoimmunology; 2015 Apr; 4(4):e992237. PubMed ID: 26137407
[TBL] [Abstract][Full Text] [Related]
2. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
[TBL] [Abstract][Full Text] [Related]
3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
4. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.
Kim IK; Kim BS; Koh CH; Seok JW; Park JS; Shin KS; Bae EA; Lee GE; Jeon H; Cho J; Jung Y; Han D; Kwon BS; Lee HY; Chung Y; Kang CY
Nat Med; 2015 Sep; 21(9):1010-7. PubMed ID: 26280119
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
[TBL] [Abstract][Full Text] [Related]
7. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
8. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
9. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
Zhou P; L'italien L; Hodges D; Schebye XM
J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
[TBL] [Abstract][Full Text] [Related]
10. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
11. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
Coe D; Begom S; Addey C; White M; Dyson J; Chai JG
Cancer Immunol Immunother; 2010 Sep; 59(9):1367-77. PubMed ID: 20480365
[TBL] [Abstract][Full Text] [Related]
12. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
Draghiciu O; Lubbers J; Nijman HW; Daemen T
Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
[TBL] [Abstract][Full Text] [Related]
13. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma.
Pan C; Wu Q; Wang S; Mei Z; Zhang L; Gao X; Qian J; Xu Z; Zhang K; Su R; Guo D; Zhou L; Zheng S
Oncoimmunology; 2022; 11(1):2073010. PubMed ID: 35558158
[TBL] [Abstract][Full Text] [Related]
14. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
16. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
17. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
[TBL] [Abstract][Full Text] [Related]
19. GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells.
Koh CH; Kim IK; Shin KS; Jeon I; Song B; Lee JM; Bae EA; Seo H; Kang TS; Kim BS; Chung Y; Kang CY
Cancer Immunol Res; 2020 May; 8(5):698-709. PubMed ID: 32122993
[TBL] [Abstract][Full Text] [Related]
20. GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC.
Wiles KN; Tsikretsis LE; Alioto CM; Hermida de Viveiros PA; Villaflor VM; Tétreault MP
Carcinogenesis; 2022 Oct; 43(9):908-918. PubMed ID: 35880612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
